Platform & Pipeline
Lead Product.
A Better Solution for Pancreatic Cancer
What is Pancreatic Cancer?
Pancreatic cancer is one of the deadliest forms of cancer with an annual incidence of ~496,000 cases worldwide resulting in over 466,000 deaths. Chemotherapy, particularly a combined regimen, remains an important neoadjuvant and/or adjuvant treatment for pancreatic cancer.
Anatomy of Our Lead Product
DUO-207: Gemcitabine/Paclitaxel Nanomedicine
Our nanomedicine platform delivers gemcitabine (GEM) and paclitaxel (PTX), a first-line pancreatic cancer therapy for some patients.
As DUO-207, this nanomedicine features distinct advantages over sequential administration of free drug agents: 1) simultaneous delivery of GEM/PTX, 2) improved dosing/prolonged activity, and 3) 10-30nm micelles deliver therapy to tumor tissue.
Because of its small size, DUO-207 is highly effective at penetrating solid tumor, including treatment-resistant patient-derived xenografts (at right).
DUO-207 (light blue) halts the growth of human derived tumors that remain unchecked by standard of care (dark blue). Negative control shown in red.